Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17132155 | ANTAGONISTS OF ACTIVIN-ACTRIIA AND USES FOR INCREASING RED BLOOD CELL LEVELS | December 2020 | June 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17132024 | ACTIVIN-ACTRII ANTAGONISTS AND USES FOR INCREASING RED BLOOD CELL LEVELS | December 2020 | May 2023 | Abandon | 29 | 0 | 1 | No | No |
| 17121893 | B7-H3 Antibody, Antigen-Binding Fragment Thereof And Medical Use Thereof | December 2020 | February 2023 | Allow | 26 | 1 | 0 | Yes | No |
| 17115021 | NUCLEIC ACIDS ENCODING ANTI-OX40L ANTIBODIES | December 2020 | July 2022 | Allow | 20 | 0 | 0 | Yes | No |
| 17108731 | HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODIES TO CD47 | December 2020 | January 2021 | Allow | 2 | 0 | 0 | Yes | No |
| 17059886 | A MONOCLONAL ANTIBODY AGAINST NAV1.7 | November 2020 | January 2023 | Allow | 26 | 1 | 0 | Yes | No |
| 17058076 | BLOCKING ANTIBODIES AGAINST CD47 AND METHODS OF USE THEREOF | November 2020 | November 2022 | Allow | 24 | 1 | 0 | Yes | No |
| 17056243 | ANTIBODIES AND ANTIBODY FRAGMENTS AGAINST HNAV1.7 CHANNEL AND THEIR USE IN PAIN AND CANCER INDICATIONS | November 2020 | January 2023 | Allow | 26 | 1 | 1 | No | No |
| 17082525 | Preparation of Type I Collagen-Like Fiber and Method for Regulating and Controlling the D-periodic of Fiber Thereof | October 2020 | February 2023 | Allow | 28 | 3 | 1 | Yes | No |
| 17048442 | MONOCLONAL ANTIBODY AGAINST NERVE GROWTH FACTOR, AND ENCODING GENE AND USE THEREOF | October 2020 | August 2022 | Allow | 60 | 0 | 0 | Yes | No |
| 17066215 | FUSION PROTEINS FOR OPHTHALMOLOGY WITH INCREASED EYE RETENTION | October 2020 | January 2023 | Allow | 28 | 1 | 0 | Yes | No |
| 17065151 | ANTI-GALECTIN-1 (GAL1) MONOCLONAL ANTIBODIES AND FRAGMENTS THEREOF FOR NEUTRALIZING GAL1 | October 2020 | January 2023 | Allow | 27 | 2 | 1 | No | No |
| 17045166 | ANTI-HUMAN LAG-3 MONOCLONAL ANTIBODY AND USE THEREOF | October 2020 | February 2023 | Allow | 28 | 2 | 0 | Yes | No |
| 17061219 | METHODS OF TREATMENT BY TARGETING VCAM1 AND MAEA | October 2020 | March 2023 | Allow | 30 | 1 | 1 | Yes | No |
| 15733657 | METHODS AND COMPOSITIONS FOR TARGETING LIVER AND LYMPH NODE SINUSOIDAL ENDOTHELIAL CELL C-TYPE LECTIN (LSECTIN) | September 2020 | March 2023 | Abandon | 29 | 2 | 1 | No | No |
| 17040343 | Treatment and Prophylaxis of Amyloidosis | September 2020 | October 2022 | Abandon | 25 | 1 | 0 | No | No |
| 16982605 | NOVEL ANTI-LAG-3 ANTIBODY POLYPEPTIDE | September 2020 | January 2023 | Allow | 28 | 2 | 0 | Yes | No |
| 15733540 | ANTI-CD73 ANTIBODIES AND USES THEREOF | August 2020 | February 2022 | Allow | 17 | 0 | 0 | Yes | No |
| 16997306 | Use of Antibody | August 2020 | August 2022 | Abandon | 24 | 0 | 1 | No | No |
| 16995573 | ANTI-OX40 BINDING PROTEINS | August 2020 | November 2022 | Allow | 27 | 2 | 1 | Yes | No |
| 16970351 | ANTI-TIGIT ANTIBODIES AND USES THEREOF | August 2020 | August 2022 | Allow | 24 | 1 | 0 | No | No |
| 16968296 | ANTIBODY AGAINST ALPHA-11 INTEGRIN AND ITS USE | August 2020 | December 2022 | Abandon | 28 | 1 | 1 | No | No |
| 16967016 | ANTI-B7-H4 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF | August 2020 | August 2022 | Allow | 24 | 1 | 0 | No | No |
| 16939657 | COMPOSITIONS AND METHODS FOR TREATING SEXUAL DYSFUNCTION | July 2020 | June 2022 | Abandon | 23 | 0 | 1 | No | No |
| 16933263 | Methods of Modulating Lymphangiogenesis, E.g., to Treat Corneal Transplant Rejection, in a Subject | July 2020 | June 2022 | Abandon | 23 | 0 | 1 | No | No |
| 16924628 | ANTIGEN BINDING PROTEINS TO ONCOSTATIN M (OSM) | July 2020 | September 2022 | Abandon | 27 | 0 | 1 | No | No |
| 16907932 | ANTIBODIES TO SYMMETRICALLY DIMETHYLATED ARGININE ANALYTES AND USE THEREOF | June 2020 | October 2020 | Allow | 4 | 0 | 0 | No | No |
| 16956318 | SPARC Assay | June 2020 | January 2023 | Abandon | 31 | 1 | 0 | No | No |
| 16905211 | ANTIBODY | June 2020 | December 2020 | Allow | 6 | 0 | 1 | Yes | No |
| 16770217 | Methods of Managing Hepatic Steatosis | June 2020 | October 2022 | Abandon | 29 | 2 | 0 | No | No |
| 16768611 | LEUKAEMIC STEM CELLS | May 2020 | April 2023 | Abandon | 34 | 0 | 1 | No | No |
| 16768151 | METHOD | May 2020 | April 2023 | Abandon | 34 | 1 | 0 | No | No |
| 16765100 | BINDING UNIT TARGETING FIBROBLAST ACTIVATION PROTEIN ALPHA AND APPLICATION THEREOF | May 2020 | May 2022 | Allow | 24 | 2 | 1 | Yes | No |
| 16762895 | IL2RBETA/COMMON GAMMA CHAIN ANTIBODIES | May 2020 | April 2023 | Allow | 35 | 2 | 0 | Yes | No |
| 16759964 | BISPECIFIC ANTIBODY CONSTRUCTS AND METHODS OF USE | April 2020 | February 2022 | Allow | 21 | 2 | 1 | Yes | No |
| 16759644 | Uses of Irisin | April 2020 | June 2022 | Abandon | 26 | 2 | 1 | No | No |
| 16847130 | ANTIBODIES AGAINST OX-40 AND USES THEREOF | April 2020 | May 2022 | Allow | 25 | 2 | 1 | No | No |
| 16840844 | BIOLOGICAL MATERIALS AND USES THEREOF | April 2020 | September 2022 | Abandon | 29 | 1 | 1 | No | No |
| 16753670 | METHOD AND COMPOSITION FOR TREATING HEPATOCELLULAR CARCINOMA WITHOUT VIRAL INFECTION BY CONTROLLING THE LIPID HOMEOSTASIS | April 2020 | December 2022 | Abandon | 33 | 2 | 1 | No | No |
| 16652966 | METHODS FOR TARGETING THE IMMUNE CHECKPOINT PD1 PATHWAY FOR TREATING PULMONARY FIBROSIS | April 2020 | March 2023 | Allow | 35 | 6 | 1 | Yes | No |
| 16652384 | PROTEIN BINDING TO FIBRONECTIN B DOMAIN | March 2020 | August 2021 | Allow | 16 | 1 | 1 | Yes | No |
| 16828553 | ALPHA-V BETA-8 ANTIBODIES | March 2020 | May 2023 | Abandon | 38 | 2 | 1 | No | No |
| 16821064 | CD8A-Binding Fibronectin Type III Domains | March 2020 | December 2021 | Allow | 21 | 1 | 1 | No | No |
| 16819036 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | March 2020 | November 2021 | Allow | 20 | 0 | 1 | Yes | No |
| 16808451 | ANTIBODY | March 2020 | August 2021 | Abandon | 18 | 0 | 1 | No | No |
| 16805058 | PEPTIDES AND RELATED COMPOSITIONS AND METHODS | February 2020 | May 2022 | Allow | 26 | 1 | 1 | Yes | No |
| 16642995 | ANTI-TM4SF1 ANTIBODIES AND METHODS OF USING SAME | February 2020 | September 2021 | Allow | 18 | 1 | 1 | Yes | No |
| 16799703 | Anti-CD303 Monoclonal Antibodies | February 2020 | January 2022 | Abandon | 23 | 1 | 1 | No | No |
| 16641263 | ROUNDABOUT (ROBO) RECEPTOR INHIBITORS AND USES THEREOF | February 2020 | May 2022 | Allow | 26 | 3 | 1 | Yes | No |
| 16795296 | INTEGRIN BETA7 ANTAGONISTS AND METHODS OF TREATING CROHN'S DISEASE | February 2020 | April 2022 | Abandon | 26 | 1 | 1 | No | No |
| 16792925 | ISOLATED POLYPEPTIDES OF CD44 AND USES THEREOF | February 2020 | September 2022 | Allow | 31 | 2 | 1 | No | No |
| 16791975 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASE ASSOCIATED WITH ALPHA-V BETA-8 INTEGRIN | February 2020 | July 2022 | Allow | 29 | 1 | 1 | Yes | No |
| 16788251 | NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWIS A | February 2020 | July 2023 | Abandon | 42 | 2 | 0 | Yes | Yes |
| 16783623 | METHOD FOR DETERMINING ANTI-DRUG ANTIBODIES IN A MINIPIG SAMPLE | February 2020 | December 2021 | Allow | 22 | 0 | 0 | Yes | No |
| 16781647 | METHODS OF ADMINISTERING BETA7 INTEGRIN ANTAGONISTS | February 2020 | April 2022 | Abandon | 26 | 1 | 1 | No | No |
| 16773907 | METHODS OF TREATMENT BY TARGETING VCAM1 AND MAEA | January 2020 | October 2021 | Allow | 21 | 2 | 1 | Yes | No |
| 16745178 | Anti-MCAM Antibodies And Associated Methods Of Use | January 2020 | November 2021 | Abandon | 22 | 1 | 0 | Yes | No |
| 16628512 | ROR1 ANTIBODIES | January 2020 | April 2022 | Allow | 28 | 1 | 0 | Yes | No |
| 16626630 | USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES FOR THE TREATMENT OF GLAUCOMA | December 2019 | April 2023 | Allow | 39 | 3 | 2 | Yes | No |
| 16626621 | USE OF ANTI-FAM19A5 ANTIBODIES FOR TREATING FIBROSIS | December 2019 | June 2021 | Allow | 18 | 1 | 1 | Yes | No |
| 16724407 | ANTI-CD40 ANTIBODIES AND USES THEREOF | December 2019 | March 2020 | Allow | 2 | 0 | 1 | Yes | No |
| 16724396 | CD40 BINDING ANTIBODIES AND USES THEREOF | December 2019 | February 2020 | Allow | 2 | 0 | 1 | Yes | No |
| 16724385 | CD40 SPECIFIC ANTIBODIES AND USES THEREOF | December 2019 | February 2020 | Allow | 2 | 0 | 1 | Yes | No |
| 16724409 | ANTIBODIES SPECIFIC TO CD40 AND USES THEREOF | December 2019 | February 2020 | Allow | 2 | 0 | 1 | Yes | No |
| 16726160 | ANTIBODIES TARGETING CD40 AND USES THEREOF | December 2019 | February 2020 | Allow | 2 | 0 | 1 | Yes | No |
| 16723897 | ANTIBODIES TO SYMMETRICALLY DIMETHYLATED ARGININE ANALYTES AND USE THEREOF | December 2019 | April 2020 | Allow | 3 | 0 | 1 | Yes | No |
| 16723424 | MESENCHYMAL STEM CELL DIFFERENTIATION | December 2019 | September 2021 | Allow | 21 | 1 | 1 | No | No |
| 16707157 | ANTI-TENASCIN C ANTIBODIES AND USES THEREOF | December 2019 | January 2021 | Allow | 13 | 0 | 0 | No | No |
| 16705538 | ENGINEERED ANTIBODY FOR INHIBITION OF FIBROSIS | December 2019 | August 2021 | Allow | 21 | 1 | 1 | Yes | No |
| 16619496 | HUMANIZED ANTI-N-CADHERIN ANTIBODIES AND USES THEREOF | December 2019 | July 2023 | Abandon | 44 | 2 | 1 | No | Yes |
| 16702692 | SELECTIVE TARGETING OF THE CD40L/MAC-1 INTERACTION BY SMALL PEPTIDE INHIBITORS AND ITS USE FOR THE TREATMENT OF INFLAMMATION AND ATHEROGENESIS | December 2019 | January 2021 | Allow | 13 | 0 | 1 | Yes | No |
| 16617254 | METHODS FOR THE TREATMENT OF CHRONIC POUCHITIS | November 2019 | May 2022 | Abandon | 29 | 0 | 1 | No | No |
| 16687385 | Anti- PODXL Antibody MAI1738 and Its Use for Cancer Treatment | November 2019 | January 2022 | Allow | 26 | 1 | 0 | Yes | No |
| 16614701 | ANTI-ROBO2 ANTIBODIES, COMPOSITIONS, METHODS AND USES THEREOF | November 2019 | February 2022 | Allow | 27 | 1 | 1 | Yes | No |
| 16614777 | NOVEL MONOCLONAL ANTIBODIES TO CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4 (CTLA-4) | November 2019 | December 2022 | Allow | 37 | 3 | 1 | Yes | No |
| 16685876 | METHODS FOR TREATING HYPERLIPIDEMIA WITH AN ANGPTL8 INHIBITOR AND AN ANGPTL3 INHIBITOR | November 2019 | March 2022 | Abandon | 28 | 2 | 1 | No | No |
| 16683644 | BIOMARKERS FOR USE IN INTEGRIN THERAPY APPLICATIONS | November 2019 | June 2021 | Abandon | 19 | 0 | 1 | No | No |
| 16677319 | Methods for Treating Patients with Familial Hypercholesterolemia | November 2019 | September 2022 | Abandon | 34 | 2 | 1 | No | No |
| 16611209 | HUMAN ANTI-SEMAPHORIN 4D ANTIBODY | November 2019 | April 2022 | Allow | 30 | 2 | 0 | Yes | No |
| 16610071 | ANTI-PD-L1 ANTIBODIES AND USES THEREOF | October 2019 | August 2021 | Allow | 22 | 0 | 0 | Yes | No |
| 16663131 | ANTI-OX40 ANTIBODIES AND THEIR USES | October 2019 | November 2019 | Allow | 1 | 0 | 0 | Yes | No |
| 16606647 | ANTI-PD-L1 ANTIBODY AND USE THEREOF | October 2019 | April 2022 | Abandon | 30 | 1 | 0 | No | No |
| 16601539 | ANTI-OX40 ANTIBODIES AND USES THEREOF | October 2019 | April 2021 | Allow | 18 | 1 | 1 | No | No |
| 16590628 | ANTI-LAG3 ANTIBODIES | October 2019 | March 2023 | Allow | 41 | 2 | 1 | Yes | No |
| 16588331 | ANTIBODIES TO INTEGRIN AVB6 AND USE OF SAME TO TREAT CANCER | September 2019 | May 2021 | Abandon | 19 | 0 | 1 | No | No |
| 16499674 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH A COMBINATION OF AN ANTAGONIST OF PD-1 AND AN ANTI-CTLA4 ANTIBODY | September 2019 | January 2023 | Abandon | 40 | 2 | 1 | No | No |
| 16583839 | ANTIBODIES AGAINST HUMAN ANGIOPOIETIN 2 | September 2019 | June 2021 | Abandon | 21 | 1 | 0 | No | No |
| 16497687 | B7-H3 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF | September 2019 | October 2020 | Allow | 13 | 0 | 0 | Yes | No |
| 16497612 | ANTI-EMAP II ANTIBODY AND USE THEREOF | September 2019 | April 2021 | Allow | 19 | 1 | 0 | Yes | No |
| 16577004 | METHODS FOR TREATING OR PREVENTING ATHEROSCLEROSIS BY ADMINISTERING AN INHIBITOR OF ANGPTL3 | September 2019 | January 2022 | Abandon | 28 | 2 | 1 | No | No |
| 16495528 | HUMANIZED ANTI-CD40 ANTIBODIES | September 2019 | June 2021 | Abandon | 21 | 1 | 0 | No | No |
| 16480014 | ANTI-PD-1 MONOCLONAL ANTIBODY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | September 2019 | October 2021 | Allow | 27 | 0 | 1 | Yes | No |
| 16561991 | ENDOGLIN PEPTIDES TO TREAT FIBROTIC DISEASES | September 2019 | September 2022 | Allow | 37 | 3 | 1 | Yes | No |
| 16561439 | MONOCLONAL ANTIBODY AND ANTIGENS FOR DIAGNOSING AND TREATING LUNG DISEASE AND INJURY | September 2019 | June 2021 | Abandon | 22 | 1 | 1 | No | No |
| 16560143 | ANTI-NR10 ANTIBODY AND USE THEREOF | September 2019 | December 2022 | Abandon | 39 | 0 | 1 | No | No |
| 16490472 | ANTI-GPR20 ANTIBODY | August 2019 | October 2021 | Allow | 26 | 1 | 1 | Yes | No |
| 16556952 | DISINTEGRIN VARIANTS AND PHARMACEUTICAL USES THEREOF | August 2019 | October 2020 | Allow | 14 | 0 | 1 | Yes | No |
| 16549462 | SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS | August 2019 | August 2021 | Allow | 24 | 2 | 1 | No | No |
| 16487321 | TIM-3 ANTIBODY, ANTIGEN BINDING FRAGMENT THEREOF, AND MEDICINAL USES THEREOF | August 2019 | February 2022 | Allow | 30 | 2 | 1 | Yes | No |
| 16487330 | CANCER TREATMENT USING ANTIBODIES THAT BIND CYTOTOXIC T-LYMPHOCYTE ANTIGEN-4 (CTLA-4) | August 2019 | January 2022 | Allow | 28 | 1 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HADDAD, MAHER M.
With a 21.7% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 10.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HADDAD, MAHER M works in Art Unit 1644 and has examined 1,136 patent applications in our dataset. With an allowance rate of 36.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.
Examiner HADDAD, MAHER M's allowance rate of 36.4% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by HADDAD, MAHER M receive 1.72 office actions before reaching final disposition. This places the examiner in the 33% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by HADDAD, MAHER M is 31 months. This places the examiner in the 53% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +64.7% benefit to allowance rate for applications examined by HADDAD, MAHER M. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 16.6% of applications are subsequently allowed. This success rate is in the 15% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 36.3% of cases where such amendments are filed. This entry rate is in the 56% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 40.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 37% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 62.9% of appeals filed. This is in the 42% percentile among all examiners. Of these withdrawals, 74.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 82.8% are granted (fully or in part). This grant rate is in the 85% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 1.8% of allowed cases (in the 74% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.0% of allowed cases (in the 62% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.